Skip to main content
Erschienen in: Journal of Gastroenterology 1/2020

19.09.2019 | Original Article—Liver, Pancreas, and Biliary Tract

Diagnostic accuracy of combined biomarker measurements and vibration-controlled transient elastography (VCTE) for predicting fibrosis stage of non-alcoholic fatty liver disease

verfasst von: Toshihide Shima, Kyoko Sakai, Hirohisa Oya, Takayuki Katayama, Yasuhide Mitsumoto, Masayuki Mizuno, Yoshihiro Kanbara, Takeshi Okanoue

Erschienen in: Journal of Gastroenterology | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Numerous biomarkers have been developed for assessing the presence and severity of liver fibrosis associated with non-alcoholic fatty liver disease (NAFLD). Fibrosis can be assessed by liver stiffness measurement (LSM) using vibration-controlled transient elastography (VCTE). Here we examined whether diagnostic accuracy and applicability can be further improved by combining various biomarker measurements with LSM.

Methods

A total of 278 patients with biopsy-confirmed Japanese NAFLD patients were enrolled. Area under the receiver operator characteristic curve (AUROC) was evaluated for obtaining the optimum interpretation criteria for LSM by VCTE and comparing various biomarkers alone and in combination with LSM.

Results

Liver stiffness measurements including cases with interquartile range (IQR)/median (M) < 30% or LSM ≤ 7.1 kPa demonstrated high applicability (90% of patients with NAFLD) and accuracy (AUROC: 0.891) for predicting stage ≥ 3 fibrosis. For all biomarkers tested, the AUROC values for predicting stage ≥ 3 fibrosis were increased when combined with LSM [platelet count, 0.734 vs. 0.912; type-4 collagen 7s (T4C7s), 0.894 vs. 0.921; aspartate aminotransferase to alanine aminotransferase ratio (AST/ALT), 0.774 vs. 0.906; AST to platelet ratio index, 0.789 vs. 0.902; FIB-4 index, 0.828 vs. 0.922; NAFLD fibrosis score, 0.800 vs. 0.906; CA index-fibrosis, 0.884 vs. 0.913; FM-fibro index, 0.920 vs. 0.943; FIB-4 index + T4C7s, 0.901 vs. 0.930], demonstrating the advantage of concurrent LSM.

Conclusions

While VCTE has slightly limited applicability (90%) for patients with NAFLD, concurrent measurement with certain biomarkers (especially FM-fibro, T4C7s, and FIB-4) greatly improves the diagnostic accuracy.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the study of liver diseases. Hepatology. 2018;67:328–57.PubMedCrossRef Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the study of liver diseases. Hepatology. 2018;67:328–57.PubMedCrossRef
2.
Zurück zum Zitat Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(389–97):e10. Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(389–97):e10.
3.
Zurück zum Zitat Kim D, Kim WR, Kim HJ, et al. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology. 2013;57:1357–65.PubMedCrossRef Kim D, Kim WR, Kim HJ, et al. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology. 2013;57:1357–65.PubMedCrossRef
4.
Zurück zum Zitat Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65:1557–65.PubMedCrossRef Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65:1557–65.PubMedCrossRef
5.
Zurück zum Zitat Yoshimura K, Okanoue T, Ebise H, et al. Identification of novel noninvasive markers for diagnosing nonalcoholic steatohepatitis and related fibrosis by data mining. Hepatology. 2016;63:462–73.PubMedCrossRef Yoshimura K, Okanoue T, Ebise H, et al. Identification of novel noninvasive markers for diagnosing nonalcoholic steatohepatitis and related fibrosis by data mining. Hepatology. 2016;63:462–73.PubMedCrossRef
6.
Zurück zum Zitat Okanoue T, Ebise H, Kai T, et al. A simple scoring system using type IV collagen 7s and aspartate aminotransferase for diagnosing nonalcoholic steatohepatitis and related fibrosis. J Gastroenterol. 2018;53:129–39.PubMedCrossRef Okanoue T, Ebise H, Kai T, et al. A simple scoring system using type IV collagen 7s and aspartate aminotransferase for diagnosing nonalcoholic steatohepatitis and related fibrosis. J Gastroenterol. 2018;53:129–39.PubMedCrossRef
7.
Zurück zum Zitat Kwok R, Tse YK, Wong GL, et al. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease—the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther. 2014;39:254–69.PubMedCrossRef Kwok R, Tse YK, Wong GL, et al. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease—the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther. 2014;39:254–69.PubMedCrossRef
8.
Zurück zum Zitat Yoneda M, Imajo K, Takahashi H, et al. Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods. J Gastroenterol. 2018;53:181–96.PubMedCrossRef Yoneda M, Imajo K, Takahashi H, et al. Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods. J Gastroenterol. 2018;53:181–96.PubMedCrossRef
9.
Zurück zum Zitat Younossi ZM, Loomba R, Anstee QM, et al. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology. 2018;68:349–60.PubMedCrossRef Younossi ZM, Loomba R, Anstee QM, et al. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology. 2018;68:349–60.PubMedCrossRef
10.
Zurück zum Zitat Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers. J Hepatol. 2018;68:305–15.PubMedCrossRef Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers. J Hepatol. 2018;68:305–15.PubMedCrossRef
11.
Zurück zum Zitat Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.PubMedCrossRef Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.PubMedCrossRef
12.
Zurück zum Zitat Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–9.PubMedCrossRef Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–9.PubMedCrossRef
13.
Zurück zum Zitat Kruger FC, Daniels CR, Kidd M, et al. Apri: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with Nafld/Nash. S Afr Med J. 2011;101:477–80.PubMed Kruger FC, Daniels CR, Kidd M, et al. Apri: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with Nafld/Nash. S Afr Med J. 2011;101:477–80.PubMed
14.
Zurück zum Zitat Shah AG, Lydecker A, Murray K, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7:1104–12.PubMedPubMedCentralCrossRef Shah AG, Lydecker A, Murray K, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7:1104–12.PubMedPubMedCentralCrossRef
15.
Zurück zum Zitat Angulo P, Hui JM, Marchesini G, et al. The Nafld fibrosis score: a noninvasive system that identifies liver fibrosis in patients with Nafld. Hepatology. 2007;45:846–54.PubMedCrossRef Angulo P, Hui JM, Marchesini G, et al. The Nafld fibrosis score: a noninvasive system that identifies liver fibrosis in patients with Nafld. Hepatology. 2007;45:846–54.PubMedCrossRef
16.
Zurück zum Zitat Kanda Y. Investigation of the freely available easy-to-use software ‘Ezr’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.CrossRefPubMed Kanda Y. Investigation of the freely available easy-to-use software ‘Ezr’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.CrossRefPubMed
17.
Zurück zum Zitat Kanda Y. Free Statistical Software: Ezr (Easy R) on R Commander. Kanda Y. Free Statistical Software: Ezr (Easy R) on R Commander.
18.
Zurück zum Zitat Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (Roc) curve. Radiology. 1982;143:29–36.PubMedCrossRef Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (Roc) curve. Radiology. 1982;143:29–36.PubMedCrossRef
19.
Zurück zum Zitat DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837–45.PubMedCrossRef DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837–45.PubMedCrossRef
20.
Zurück zum Zitat Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, et al. Evaluating the added predictive ability of a new marker: from area under the roc curve to reclassification and beyond. Stat Med. 2008;27:157–72 (discussion 207–212).PubMedCrossRef Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, et al. Evaluating the added predictive ability of a new marker: from area under the roc curve to reclassification and beyond. Stat Med. 2008;27:157–72 (discussion 207–212).PubMedCrossRef
21.
Zurück zum Zitat Pencina MJ, D’Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011;30:11–21.PubMedCrossRef Pencina MJ, D’Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011;30:11–21.PubMedCrossRef
22.
Zurück zum Zitat Boursier J, Zarski JP, de Ledinghen V, et al. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology. 2013;57:1182–91.PubMedCrossRef Boursier J, Zarski JP, de Ledinghen V, et al. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology. 2013;57:1182–91.PubMedCrossRef
23.
Zurück zum Zitat Dietrich CF, Bamber J, Berzigotti A, et al. Efsumb guidelines and recommendations on the clinical use of liver ultrasound elastography, update 2017 (long version). Ultraschall Med. 2017;38:e16–47.PubMed Dietrich CF, Bamber J, Berzigotti A, et al. Efsumb guidelines and recommendations on the clinical use of liver ultrasound elastography, update 2017 (long version). Ultraschall Med. 2017;38:e16–47.PubMed
24.
Zurück zum Zitat Singh S, Muir AJ, Dieterich DT, et al. American gastroenterological association institute technical review on the role of elastography in chronic liver diseases. Gastroenterology. 2017;152:1544–77.PubMedCrossRef Singh S, Muir AJ, Dieterich DT, et al. American gastroenterological association institute technical review on the role of elastography in chronic liver diseases. Gastroenterology. 2017;152:1544–77.PubMedCrossRef
25.
Zurück zum Zitat Castera L, Foucher J, Bernard PH, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology. 2010;51:828–35.PubMed Castera L, Foucher J, Bernard PH, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology. 2010;51:828–35.PubMed
26.
Zurück zum Zitat European Association for Study of L, Asociacion Latinoamericana para el Estudio del H. Easl-Aleh clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63:237–64.CrossRef European Association for Study of L, Asociacion Latinoamericana para el Estudio del H. Easl-Aleh clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63:237–64.CrossRef
27.
Zurück zum Zitat Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29:1705–13.PubMedCrossRef Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29:1705–13.PubMedCrossRef
28.
Zurück zum Zitat Arena U, Vizzutti F, Corti G, et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology. 2008;47:380–4.PubMedCrossRef Arena U, Vizzutti F, Corti G, et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology. 2008;47:380–4.PubMedCrossRef
29.
Zurück zum Zitat Millonig G, Reimann FM, Friedrich S, et al. Extrahepatic cholestasis increases liver stiffness (Fibroscan) irrespective of fibrosis. Hepatology. 2008;48:1718–23.PubMedCrossRef Millonig G, Reimann FM, Friedrich S, et al. Extrahepatic cholestasis increases liver stiffness (Fibroscan) irrespective of fibrosis. Hepatology. 2008;48:1718–23.PubMedCrossRef
30.
Zurück zum Zitat Xiao G, Zhu S, Xiao X, et al. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology. 2017;66:1486–501.PubMedCrossRef Xiao G, Zhu S, Xiao X, et al. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology. 2017;66:1486–501.PubMedCrossRef
31.
Zurück zum Zitat Yoshioka K, Hashimoto S, Kawabe N. Measurement of liver stiffness as a non-invasive method for diagnosis of non-alcoholic fatty liver disease. Hepatol Res. 2015;45:142–51.PubMedCrossRef Yoshioka K, Hashimoto S, Kawabe N. Measurement of liver stiffness as a non-invasive method for diagnosis of non-alcoholic fatty liver disease. Hepatol Res. 2015;45:142–51.PubMedCrossRef
32.
Zurück zum Zitat Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European liver fibrosis panel and exploring simple markers. Hepatology. 2008;47:455–60.PubMedCrossRef Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European liver fibrosis panel and exploring simple markers. Hepatology. 2008;47:455–60.PubMedCrossRef
33.
Zurück zum Zitat Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology. 2004;127:1704–13.PubMedCrossRef Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology. 2004;127:1704–13.PubMedCrossRef
34.
Zurück zum Zitat Chen J, Yin M, Talwalkar JA, et al. Diagnostic performance of Mr elastography and vibration-controlled transient elastography in the detection of hepatic fibrosis in patients with severe to morbid obesity. Radiology. 2017;283:418–28.PubMedCrossRef Chen J, Yin M, Talwalkar JA, et al. Diagnostic performance of Mr elastography and vibration-controlled transient elastography in the detection of hepatic fibrosis in patients with severe to morbid obesity. Radiology. 2017;283:418–28.PubMedCrossRef
35.
Zurück zum Zitat Hsu C, Caussy C, Imajo K, et al. Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants. Clin Gastroenterol Hepatol. 2018. Hsu C, Caussy C, Imajo K, et al. Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants. Clin Gastroenterol Hepatol. 2018.
36.
Zurück zum Zitat Cui J, Heba E, Hernandez C, et al. Magnetic resonance elastography is superior to acoustic radiation force impulse for the diagnosis of fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease: a prospective study. Hepatology. 2016;63:453–61.PubMedCrossRef Cui J, Heba E, Hernandez C, et al. Magnetic resonance elastography is superior to acoustic radiation force impulse for the diagnosis of fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease: a prospective study. Hepatology. 2016;63:453–61.PubMedCrossRef
37.
Zurück zum Zitat Imajo K, Kessoku T, Honda Y, et al. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterology. 2016;150(626–37):e7. Imajo K, Kessoku T, Honda Y, et al. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterology. 2016;150(626–37):e7.
38.
Zurück zum Zitat Park CC, Nguyen P, Hernandez C, et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology. 2017;152(598–607):e2. Park CC, Nguyen P, Hernandez C, et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology. 2017;152(598–607):e2.
39.
Zurück zum Zitat Petta S, Vanni E, Bugianesi E, et al. The combination of liver stiffness measurement and Nafld fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. Liver Int. 2015;35:1566–73.PubMedCrossRef Petta S, Vanni E, Bugianesi E, et al. The combination of liver stiffness measurement and Nafld fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. Liver Int. 2015;35:1566–73.PubMedCrossRef
40.
Zurück zum Zitat Boursier J, Vergniol J, Sawadogo A, et al. The combination of a blood test and fibroscan improves the non-invasive diagnosis of liver fibrosis. Liver Int. 2009;29:1507–15.PubMedCrossRef Boursier J, Vergniol J, Sawadogo A, et al. The combination of a blood test and fibroscan improves the non-invasive diagnosis of liver fibrosis. Liver Int. 2009;29:1507–15.PubMedCrossRef
41.
Zurück zum Zitat Ducancelle A, Leroy V, Vergniol J, et al. A single test combining blood markers and elastography is more accurate than other fibrosis tests in the main causes of chronic liver diseases. J Clin Gastroenterol. 2017;51:639–49.PubMedCrossRef Ducancelle A, Leroy V, Vergniol J, et al. A single test combining blood markers and elastography is more accurate than other fibrosis tests in the main causes of chronic liver diseases. J Clin Gastroenterol. 2017;51:639–49.PubMedCrossRef
42.
Zurück zum Zitat Heo JY, Kim BK, Park JY, et al. Combination of transient elastography and an enhanced liver fibrosis test to assess the degree of liver fibrosis in patients with chronic hepatitis B. Gut Liver. 2018;12:190–200.PubMedCrossRef Heo JY, Kim BK, Park JY, et al. Combination of transient elastography and an enhanced liver fibrosis test to assess the degree of liver fibrosis in patients with chronic hepatitis B. Gut Liver. 2018;12:190–200.PubMedCrossRef
43.
Zurück zum Zitat Boursier J, de Ledinghen V, Zarski JP, et al. A new combination of blood test and fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C. Am J Gastroenterol. 2011;106:1255–63.PubMedCrossRef Boursier J, de Ledinghen V, Zarski JP, et al. A new combination of blood test and fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C. Am J Gastroenterol. 2011;106:1255–63.PubMedCrossRef
44.
Zurück zum Zitat Cales P, Boursier J, Ducancelle A, et al. Improved fibrosis staging by elastometry and blood test in chronic hepatitis C. Liver Int. 2014;34:907–17.PubMedCrossRef Cales P, Boursier J, Ducancelle A, et al. Improved fibrosis staging by elastometry and blood test in chronic hepatitis C. Liver Int. 2014;34:907–17.PubMedCrossRef
45.
Zurück zum Zitat Voican CS, Louvet A, Trabut JB, et al. Transient elastography alone and in combination with Fibrotest((R)) for the diagnosis of hepatic fibrosis in alcoholic liver disease. Liver Int. 2017;37:1697–705.PubMedCrossRef Voican CS, Louvet A, Trabut JB, et al. Transient elastography alone and in combination with Fibrotest((R)) for the diagnosis of hepatic fibrosis in alcoholic liver disease. Liver Int. 2017;37:1697–705.PubMedCrossRef
46.
Zurück zum Zitat Dincses E, Yilmaz Y. Diagnostic usefulness of fibrometer Vcte for hepatic fibrosis in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2015;27:1149–53.PubMedCrossRef Dincses E, Yilmaz Y. Diagnostic usefulness of fibrometer Vcte for hepatic fibrosis in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2015;27:1149–53.PubMedCrossRef
47.
Zurück zum Zitat Loong TC, Wei JL, Leung JC, et al. Application of the combined fibrometer vibration-controlled transient elastography algorithm in chinese patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2017;32:1363–9.PubMedCrossRef Loong TC, Wei JL, Leung JC, et al. Application of the combined fibrometer vibration-controlled transient elastography algorithm in chinese patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2017;32:1363–9.PubMedCrossRef
48.
Zurück zum Zitat Myers RP, Pomier-Layrargues G, Kirsch R, et al. Feasibility and diagnostic performance of the Fibroscan Xl probe for liver stiffness measurement in overweight and obese patients. Hepatology. 2012;55:199–208.PubMedCrossRef Myers RP, Pomier-Layrargues G, Kirsch R, et al. Feasibility and diagnostic performance of the Fibroscan Xl probe for liver stiffness measurement in overweight and obese patients. Hepatology. 2012;55:199–208.PubMedCrossRef
49.
Zurück zum Zitat de Ledinghen V, Wong VW, Vergniol J, et al. Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and Xl probe of Fibroscan(R). J Hepatol. 2012;56:833–9.PubMedCrossRef de Ledinghen V, Wong VW, Vergniol J, et al. Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and Xl probe of Fibroscan(R). J Hepatol. 2012;56:833–9.PubMedCrossRef
50.
Zurück zum Zitat Vuppalanchi R, Siddiqui MS, Van Natta ML, et al. Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease. Hepatology. 2018;67:134–44.PubMedCrossRef Vuppalanchi R, Siddiqui MS, Van Natta ML, et al. Performance characteristics of vibration-controlled transient elastography for evaluation of nonalcoholic fatty liver disease. Hepatology. 2018;67:134–44.PubMedCrossRef
Metadaten
Titel
Diagnostic accuracy of combined biomarker measurements and vibration-controlled transient elastography (VCTE) for predicting fibrosis stage of non-alcoholic fatty liver disease
verfasst von
Toshihide Shima
Kyoko Sakai
Hirohisa Oya
Takayuki Katayama
Yasuhide Mitsumoto
Masayuki Mizuno
Yoshihiro Kanbara
Takeshi Okanoue
Publikationsdatum
19.09.2019
Verlag
Springer Japan
Erschienen in
Journal of Gastroenterology / Ausgabe 1/2020
Print ISSN: 0944-1174
Elektronische ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-019-01626-1

Weitere Artikel der Ausgabe 1/2020

Journal of Gastroenterology 1/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.